ClinicalTrials.gg
CompletedNCT01485796Updated May 19, 2021Results posted

Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD

A Phase 2/3 interventional study of Immune Globulin Infusion (Human), 10% and Recombinant human hyaluronidase in Primary Immunodeficiency Diseases (PID), sponsored by Baxalta now part of Shire. Completed at 10 sites in United States. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2021-05-19.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 2/3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
54
Allocation
Not applicable
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Primary Immunodeficiency Diseases by Takeda — 2 open to participants now, 3 under way, 1 of them phase 3. Primary Immunodeficiency Diseases · Takeda.

Enrollment
7th of 18
54 · median 47
Started
2011
with 1 other
Phase 2/3
5 of 23
none open now
Registered
9th of 23
by date

Among the 23 studies in Primary Immunodeficiency Diseases by Takeda, this one is the 7th largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2011, is one of 5 in phase 2/3, and was the 9th registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 23 studies in Primary Immunodeficiency Diseases by Takeda are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Primary Immunodeficiency Diseases by Takeda, or all of them as a file.
02

Study summary

The purpose of the study is to acquire additional data on safety and tolerability of recombinant human hyaluronidase (rHuPH20) facilitated subcutaneous treatment of Immune Globulin Infusion (Human), 10% (IGI, 10%) and to assess the mode of product administration.

Following a discussion with the FDA at the end of July 2012, all participants still active in the study stopped treatment with rHuPH20 to assure safety of the participants participating in the study and went into a safety follow-up.

During this safety follow-up period, participants underwent treatment with the licensed product IGI, 10% (Gammagard Liquid). The intravenous or subcutaneous administration route was at the discretion of the participant and the investigator.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)

Keywords

  • PIDD
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject must have a documented diagnosis of a form of primary humoral immunodeficiency involving a defect in antibody formation and requiring gammaglobulin replacement, as defined according to the IUIS Scientific Committee 2009 and by diagnostic criteria according to Conley et al. The diagnosis must be reviewed by the Medical Director prior to enrollment.
  • Subject is 2 years or older at the time of screening.
  • Written is obtained from either the subject or the subject's legally authorized representative prior to any study-related procedures and study product administration.
  • Subject has been receiving a consistent dose of immunoglobulin G (IgG) with a non-Baxter product (Gammunex administered IV, Hizentra, or Privigen), administered in compliance with the respective product information, for a period of at least 3 months prior to screening. The average minimum pre-study dose over that interval was equivalent to 300 mg/kg BW/4 weeks and a maximum dose equivalent to 600 mg/kg BW/4 weeks at a dosing frequency as follows:

    • For IV treatment prior to the study: at mean intervals of 3 or 4 weeks (+/- 3 days) or
    • For SC treatment prior to the study: at mean intervals of approximately 1 or 2 weeks (+/- 2 days).
  • Subject has a serum trough level of IgG > 5 g/L at screening.
  • Subject has not had a serious bacterial infection within the 3 months prior to screening.
  • If female of , subject presents with a negative pregnancy test and agrees to employ adequate measures for the duration of the study.
  • Subject is willing and able to comply with the requirements of the protocol.

Exclusion criteria

Exclusion Criteria:

  • Subject has a known history of or is positive at screening for one or more of the following: surface antigen (HBsAg), polymerase chain reaction (PCR) for virus (HCV), PCR for (HIV) Type 1/2.
  • Abnormal laboratory values at screening meeting any one of the following criteria (abnormal tests may be repeated once to determine if they are persistent):

    • Persistent (ALT) and aspartate amino transferase (AST) > 2.5 times the for the testing laboratory
    • Persistent severe neutropenia (defined as an [ANC] \<= 500/mm3).
  • Subject has (CLcr) value that is \<60% of normal for age and gender either measured, or calculated according to a gender-specific formula provided in the study protocol.
  • Subject has been diagnosed with or has a (other than adequately treated basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix), unless the disease-free period prior to screening exceeds 5 years
  • Subject is receiving anti-coagulation therapy or has a history of thrombotic episodes (including deep vein thrombosis, myocardial infarction, cerebrovascular accident, pulmonary embolism) within 12 months prior to screening or a history of thrombophilia.
  • Subject has abnormal protein loss (protein losing enteropathy, nephrotic syndrome).
  • Subject has anemia that would preclude phlebotomy for laboratory studies, according to standard practice at the site.
  • Subject has an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IV immunoglobulin, SC immunoglobulin, and/or Immune Serum Globulin (ISG) infusions.
  • Subject has immunoglobulin A (IgA) deficiency (IgA less than 0.07g/L) and known anti IgA antibodies.
  • Subject has a known allergy to hyaluronidase.
  • Subject is on preventative (prophylactic) systemic antibacterial antibiotics at doses sufficient to treat or prevent bacterial infections, and cannot stop these antibiotics at the time of screening.
  • Subject has active infection and is receiving antibiotic therapy for the treatment of infection at the time of screening.
  • Subject has a bleeding disorder or a count less than 20,000/μL, or who, in the opinion of the investigator, would be at significant risk of increased bleeding or bruising as a result of SC therapy.
  • Subject has total protein > 9 g/dL or myeloma, or macroglobulinemia (IgM) or paraproteinemia.
  • Women of meeting any one of the following criteria:

    • Subject presents with a positive pregnancy test
    • Subject is breast feeding
    • Subject intends to begin nursing during the course of the study
    • Subject does not agree to employ adequate birth-control measures (e.g. intrauterine device, diaphragm or condom [for male partner] with spermicidal jelly or foam, or pills/patches) throughout the course of the study.
  • Subject has participated in another clinical study and has been exposed to an product (IP) or device within 30 days prior to study enrollment (exception: treatment with immunoglobulin pre-study).
  • Subject is scheduled to participate in another (non-Baxter) clinical study involving an IP or device during the course of the study.
  • Subject has severe dermatitis that would preclude adequate sites for safe product administration.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
54 participants (actual)

Study arms

  • Experimental
    Epoch 1 and Epoch 2

    In Study Epoch 1 PIDD patients that are already on intravenous treatment or subcutaneous treatment will be enrolled and treated with IGI, 10% and rHuPH20 subcutaneously, with a short dose/interval ramp-up (Epoch 1) consisting of one 1-week dose and interval and one 2-week dose and interval. The ramp-up (Epoch 1) is followed by Epoch 2 which consists of approximately 6 months (24 weeks) of IGI, 10% and rHuPH20 treatment. For subjects pretreated intravenously (IV), this treatment will occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), depending on the subject´s previous IV dosing schedule. For subjects pretreated subcutaneously (SC), treatment will also occur every 3 or 4 weeks (at a 3-week or 4-week dose, respectively), at the discretion of the investigator and subject.

    Biological: Immune Globulin Infusion (Human), 10% · Biological: Recombinant human hyaluronidase

Interventions

  • Subcutaneous administration will be used in Study Epochs 1 and 2.

    Also known as: IGI, 10%

  • rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.

    Also known as: rHuPH20

06

What researchers measure

Primary outcomes

  1. Number of Related Systemic Adverse Events (Excluding Infections)

    Time frame: 7 months (per subject)

  2. Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion

    A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.

    Time frame: 7 months (per subject)

Secondary outcomes

  1. Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2

    Time frame: 6 months (per subject)

  2. Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks

    Time frame: 6 months (per subject)

  3. Number of Related Local Adverse Events (Excluding Infections)

    Time frame: 7 months (per subject)

  4. Rate of Related Local Adverse Events (Excluding Infections) Per Infusion

    A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.

    Time frame: 7 months (per subject)

  5. Number of All Related Adverse Events (Excluding Infections)

    Time frame: 7 months (per subject)

  6. Rate of All Adverse Events (Excluding Infections) Per Infusion

    A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.

    Time frame: 7 months (per subject)

  7. Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20

    Time frame: 7 months (per subject)

  8. Trough Levels of Immunoglobulin G (IgG)

    IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.

    Time frame: 7 months (per subject)

  9. Number of Infusions Per Month in Epoch 1 and Epoch 2

    Non-parametric descriptive statistics (median, range) are provided.

    Time frame: 7 months (per subject)

  10. Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2

    Non-parametric descriptive statistics (median, range) are provided.

    Time frame: 7 months (per subject)

  11. Duration of Infusion in Epoch 1 and Epoch 2

    Non-parametric descriptive statistics (median, range) are provided.

    Time frame: 7 months (per subject)

  12. Maximum Infusion Rate in Epoch 1 and Epoch 2

    Non-parametric descriptive statistics (median, range) are provided.

    Time frame: 7 months (per subject)

  13. Number of Weeks to Reach Final 3 or 4-week Dose Interval

    Non-parametric descriptive statistics (median, range) are provided.

    Time frame: 7 months (per subject)

07

Results

Posted Apr 24, 2017
Limitations and caveats
Treatment with rHuPH20 was stopped as of August 2012 following discussion with the FDA. 26 subjects still active in Study Epoch 2 went into a safety follow-up period and were treated with IGI, 10% (GAMMAGARD LIQUID) intravenously or subcutaneously.

Participant flow

Enrollment was conducted at 16 study sites in the US.

Period 1: Epoch 1 (Ramp-up)
Participant flow — Period 1: Epoch 1 (Ramp-up)
MilestoneSubcutaneous Treatment With IGI, 10% and rHuPH20
Started37
Treated in epoch 137
Completed36
Not completed1
Withdrew: Withdrawal by subject1
Period 2: Epoch 2
Participant flow — Period 2: Epoch 2
MilestoneSubcutaneous Treatment With IGI, 10% and rHuPH20
Started36
Treated in epoch 236
Completed1
Not completed35
Withdrew: Withdrawal by subject6
Withdrew: Adverse event3
Withdrew: Switch to safety follow-up26
Overall Trial (Incl. Safety Follow-up)
Participant flow — Overall Trial (Incl. Safety Follow-up)
MilestoneSubcutaneous Treatment With IGI, 10% and rHuPH20
Started37
Treated in epoch 1 (ramp-up)37
Completed epoch 1 (ramp-up)36
Started epoch 236
Treated in epoch 236
Completed epoch 21
Switch to safety follow-up26
Completed safety follow-up24
Completed25
Not completed12
Withdrew: Withdrawal by subject in epoch 11
Withdrew: Withdrawal by subject in epoch 26
Withdrew: Adverse event in epoch 23
Withdrew: Withdrawal during safety-follow-up2

Outcome measures

PrimaryNumber of Related Systemic Adverse Events (Excluding Infections)
Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Number of Related Systemic Adverse Events (Excluding Infections)
adverse eventsSafety Analysis Set (n=37)
Number of Related Systemic Adverse Events (Excluding Infections)59
PrimaryRate of Related Systemic Adverse Events (Excluding Infections) Per Infusion

A point estimate and 95% confidence interval for the rate of related systemic adverse events per infusion was derived using a Poisson model.

Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Rate of Related Systemic Adverse Events (Excluding Infections) Per Infusion
adverse eventsSafety Analysis Set (n=37)Epoch 2 Data Set (n=36)
Epoch 10.250 (0.140 to 0.406)0.253 (0.141 to 0.413)
Epoch 20.377 (0.205 to 0.626)0.377 (0.205 to 0.626)
Epoch 1+20.324 (0.187 to 0.517)0.326 (0.186 to 0.522)
SecondaryProportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2
Time frame:
6 months (per subject)
Reported as:
Number · subjects
Proportion of Subjects Who Achieve a Treatment Interval of 3 or 4 Weeks in Epoch 2
subjectsEpoch 2 Data Set (n=36)
3 or 4-week treatment interval36
3-week treatment interval6
4-week treatment interval30
SecondaryProportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks
Time frame:
6 months (per subject)
Reported as:
Number · subjects
Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks
subjectsEpoch 2 Data Set (n=36)
Proportion of Subjects Who Maintain a Treatment Interval of 3 or 4 Weeks in Epoch 2 for 24 Weeks1
SecondaryNumber of Related Local Adverse Events (Excluding Infections)
Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Number of Related Local Adverse Events (Excluding Infections)
adverse eventsSafety Analysis Set (n=37)
Number of Related Local Adverse Events (Excluding Infections)153
SecondaryRate of Related Local Adverse Events (Excluding Infections) Per Infusion

A point estimate and 95% confidence interval for the rate of related local adverse events per infusion was derived using a Poisson model.

Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Rate of Related Local Adverse Events (Excluding Infections) Per Infusion
adverse eventsSafety Analysis Set (n=37)Epoch 2 Data Set (n=36)
Epoch 10.882 (0.581 to 1.271)0.880 (0.575 to 1.278)
Epoch 20.811 (0.541 to 1.160)0.811 (0.541 to 1.160)
Epoch 1+20.841 (0.587 to 1.159)0.840 (0.582 to 1.164)
SecondaryNumber of All Related Adverse Events (Excluding Infections)
Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Number of All Related Adverse Events (Excluding Infections)
adverse eventsSafety Analysis Set (n=37)
Number of All Related Adverse Events (Excluding Infections)212
SecondaryRate of All Adverse Events (Excluding Infections) Per Infusion

A point estimate and 95% confidence interval for the rate of adverse events per infusion was derived using a Poisson model.

Time frame:
7 months (per subject)
Reported as:
Number · adverse events
Rate of All Adverse Events (Excluding Infections) Per Infusion
adverse eventsSafety Analysis Set (n=37)Epoch 2 Data Set (n=36)
Epoch 11.645 (1.221 to 2.157)1.653 (1.221 to 2.178)
Epoch 21.642 (1.164 to 2.235)1.642 (1.164 to 2.235)
Epoch 1+21.643 (1.235 to 2.132)1.646 (1.232 to 2.145)
SecondaryNumber of Subjects Who Develop Neutralizing Antibodies to rHuPH20
Time frame:
7 months (per subject)
Reported as:
Number · subjects
Number of Subjects Who Develop Neutralizing Antibodies to rHuPH20
subjectsSafety Analysis Set (n=37)
Number of Subjects Who Develop Neutralizing Antibodies to rHuPH200
SecondaryTrough Levels of Immunoglobulin G (IgG)

IgG trough levels at the beginning of Study Epoch 1 (previous immunoglobulin treatment) and at the end of Study Epoch 2 were analyzed.

Time frame:
7 months (per subject)
Reported as:
Geometric mean · g/L
Trough Levels of Immunoglobulin G (IgG)
g/LEpoch 2 Data Set
At screening10.53 (9.46 to 11.73)
At end of Epoch 29.21 (8.28 to 10.25)
SecondaryNumber of Infusions Per Month in Epoch 1 and Epoch 2

Non-parametric descriptive statistics (median, range) are provided.

Time frame:
7 months (per subject)
Reported as:
Median · infusions
Number of Infusions Per Month in Epoch 1 and Epoch 2
infusionsSafety Analysis Set (n=37)
Epoch 12.90 (2.5 to 10.1)
Epoch 21.09 (0.6 to 2.0)
SecondaryNumber of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2

Non-parametric descriptive statistics (median, range) are provided.

Time frame:
7 months (per subject)
Reported as:
Median · infusion sites (needle sticks)
Number of Infusion Sites (Needle Sticks) Per Month in Epoch 1 and Epoch 2
infusion sites (needle sticks)Safety Analysis Set (n=37)
Epoch 12.90 (2.5 to 10.1)
Epoch 21.12 (0.6 to 3.8)
SecondaryDuration of Infusion in Epoch 1 and Epoch 2

Non-parametric descriptive statistics (median, range) are provided.

Time frame:
7 months (per subject)
Reported as:
Median · hours
Duration of Infusion in Epoch 1 and Epoch 2
hoursSafety Analysis Set (n=37)
Epoch 11.23 (0.53 to 3.10)
Epoch 21.67 (0.80 to 3.55)
SecondaryMaximum Infusion Rate in Epoch 1 and Epoch 2

Non-parametric descriptive statistics (median, range) are provided.

Time frame:
7 months (per subject)
Reported as:
Median · mL/h
Maximum Infusion Rate in Epoch 1 and Epoch 2
mL/hSafety Analysis Set (n=37)
Epoch 1240.0 (60 to 300)
Epoch 2300.0 (10 to 300)
SecondaryNumber of Weeks to Reach Final 3 or 4-week Dose Interval

Non-parametric descriptive statistics (median, range) are provided.

Time frame:
7 months (per subject)
Reported as:
Median · weeks
Number of Weeks to Reach Final 3 or 4-week Dose Interval
weeksEpoch 2 Data Set (n=36)
3-week dose interval3.0 (3 to 5)
4-week dose interval3.0 (3 to 4)

Adverse events

Collected over Overall: Approximately 1 year Per subject: 7 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Epochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37)—0/37 (0%)30/37 (81.1%)
Safety Follow-up (n=26)—1/26 (3.8%)10/26 (38.5%)
Most frequent serious events
Most frequent serious events
EventEpochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37)Safety Follow-up (n=26)
HypoglycemiaMetabolism and nutrition disorders0/371/26
Most frequent other events
Showing 10 of 33
Most frequent other events
EventEpochs 1+2 (SC Treatment w/ IGI,10% and rHuPH20, n=37)Safety Follow-up (n=26)
Infusion site painGeneral disorders21/370/26
Infusion site erythemaGeneral disorders11/370/26
HeadacheNervous system disorders10/373/26
Infusion site swellingGeneral disorders9/370/26
FatigueGeneral disorders6/370/26
NauseaGastrointestinal disorders5/371/26
Infusion site pruritusGeneral disorders5/370/26
PyrexiaGeneral disorders5/372/26
SinusitisInfections and infestations5/372/26
Upper respiratory tract infectionInfections and infestations1/373/26

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Subcutaneous Treatment With IGI, 10% and rHuPH20
<=18 years12
Between 18 and 65 years22
>=65 years3
Age, Continuous
Age, Continuous(Years)Subcutaneous Treatment With IGI, 10% and rHuPH20
Median33.0 (6 to 69)
Sex: Female, Male
Sex: Female, Male(Participants)Subcutaneous Treatment With IGI, 10% and rHuPH20
Female21
Male16
08

Study locations

10 sites
  • University of California, Irvine
    Irvine, California 92697, United States
  • IMMUNOe International Research Centers
    Thornton, Colorado 80233, United States
  • Allergy Associates of the Palm Beaches, PA
    North Palm Beach, Florida 33408, United States
  • LSU Health Sciences Center & Children´s Hospital
    New Orleans, Louisiana 70118, United States
  • Midwest Immunology
    Plymouth, Minnesota 55446, United States
  • Midlands Pediatrics PC
    Papillion, Nebraska 68046, United States
  • Winthrop Allergy and Immunology
    Mineola, New York 11501, United States
  • Oklahoma Institute of Allergy & Asthma Clinical Research
    Oklahoma City, Oklahoma 73131, United States
  • Allergy and Clinical Immunology Associates
    Pittsburgh, Pennsylvania 15241, United States
  • Allergy, Asthma & Immunology Clinic PA
    Irving, Texas 75063, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2011 to primary completion in Jan 2013, 12 months.

Results were first posted in Apr 2017, 4 years 3 months after primary completion. A results delay was requested in Sep 2014.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 2, 2011
First posted
Dec 6, 2011
StartActual
Dec 29, 2011
Primary completionActual
Jan 1, 2013
CompletionActual
Jan 1, 2013
Results delay requested
Sep 8, 2014
Results first posted
Apr 24, 2017
Last update
May 19, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 19, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01485796
Responsible party
Sponsor
First posted
Dec 6, 2011
Start date
Dec 29, 2011
Primary completion
Jan 1, 2013
Completion
Jan 1, 2013
Results posted
Apr 24, 2017
Last update
May 19, 2021

Study contacts

Study Director
study director · Takeda

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Homo sapiens whole · Hyaluronidase (human recombinant)

Start the discussion